Eukarys is pleased to announce that it has been awarded Sanofi’s Golden Ticket 2024, which provides one year of free laboratory space at BioLabs France Hôtel-Dieu. We are proud to be the first biomanufacturing technology start-up to receive this prestigious award: all previous winners were in the therapeutic or AI sectors. This recognition underscores the growing importance of biomanufacturing as a key area of innovation within the life sciences industry and confirms the transformative potential of our technology, and the achievability of Eukarÿs’ goal, to accelerate the development of more efficient and cost-effective biomanufacturing solutions, ultimately improving access to critical therapies for patients worldwide.

Eukarys is proud to announce a new milestone in its innovation journey with the support of Bpifrance as part of the DeepTech Development program and the France 2030 initiative. This recognition underlines our commitment to revolutionize biomanufacturing with our C3P3® technology, which enables higher yields and lower costs. Building on our history of innovation, Eukarys was previously honoured by Bpifrance as a winner of the prestigious i-Lab competition in 2009 and 2012. These achievements underline our long-standing commitment to developing cutting-edge technologies with high impact potential.